Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 2: Immunotherapy in Lung Cancer-Adjuvant Treatment: A New Opportunity

Video Transcription

Video Summary

Dr. Ria Shah, a thoracic medical oncologist, discusses the role of immunotherapy in early-stage lung cancer, particularly stages 2A to 3B. Traditionally, resectable lung cancer has been treated with surgery, while unresectable cases received radiotherapy or chemoradiotherapy. However, the introduction of systemic anti-cancer treatments, including immunotherapy, offers new possibilities. Adjuvant and neoadjuvant therapies are explored to increase cure rates, especially when surgery alone is insufficient. Trials such as IMPOWER 010, Checkmate 816, and Keynote 671 highlight the benefits of adjuvant and neoadjuvant immunotherapy, with significant survival improvements noted. Studies show varying success rates depending on PD-L1 expression, with the best outcomes in PD-L1 high patients. Emerging research and trials continue to refine and optimize treatment pathways, emphasizing the importance of a multidisciplinary approach in managing early lung cancer.

Asset Subtitle

Riyaz Shah, MD

Keywords

immunotherapy

early-stage lung cancer

adjuvant therapy

neoadjuvant therapy

PD-L1 expression